Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,516.32
(
-1.15%
)
US TECH 100
23,146.40
(
-1.56%
)
Dow Jones
46,069.27
(
-0.78%
)
Brent Oil
102.47
(
3.74%
)
Bitcoin
68,950.35
(
-3.30%
)
News Focus
News Focus
Post# of 257293
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122813
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 206260

Monday, 12/19/2016 8:59:44 AM

Monday, December 19, 2016 8:59:44 AM

Post# of 257293
ABBV/ENTA submit NDA for Glecaprevir/Pibrentasvir pan-genotypic HCV regimen:

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-abbvie-submission-130600551.html

Consistent with prior guidance, an MAA will be submitted to the EMA in 1Q17.

ENTA will receive a cumulative $80M in milestone payments from ABBV for G/P approval in the US, EU, and Japan.

ENTA will receive tiered royalties on worldwide sales of G/P—see #msg-126723412.

Please see #msg-122031014, #msg-126481635, and #msg-127098862 for related info.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now